These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10468506)

  • 1. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease.
    Harris GJ; Codori AM; Lewis RF; Schmidt E; Bedi A; Brandt J
    Brain; 1999 Sep; 122 ( Pt 9)():1667-78. PubMed ID: 10468506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease.
    Harris GJ; Aylward EH; Peyser CE; Pearlson GD; Brandt J; Roberts-Twillie JV; Barta PE; Folstein SE
    Arch Neurol; 1996 Apr; 53(4):316-24. PubMed ID: 8929153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.
    Aylward EH; Codori AM; Barta PE; Pearlson GD; Harris GJ; Brandt J
    Arch Neurol; 1996 Dec; 53(12):1293-6. PubMed ID: 8970459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distribution of structural neuropathology in pre-clinical Huntington's disease.
    Thieben MJ; Duggins AJ; Good CD; Gomes L; Mahant N; Richards F; McCusker E; Frackowiak RS
    Brain; 2002 Aug; 125(Pt 8):1815-28. PubMed ID: 12135972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.
    Rosas HD; Reuter M; Doros G; Lee SY; Triggs T; Malarick K; Fischl B; Salat DH; Hersch SM
    Mov Disord; 2011 Aug; 26(9):1691-7. PubMed ID: 21611979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.
    Aylward EH; Brandt J; Codori AM; Mangus RS; Barta PE; Harris GJ
    Neurology; 1994 May; 44(5):823-8. PubMed ID: 8190282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal change in basal ganglia volume in patients with Huntington's disease.
    Aylward EH; Li Q; Stine OC; Ranen N; Sherr M; Barta PE; Bylsma FW; Pearlson GD; Ross CA
    Neurology; 1997 Feb; 48(2):394-9. PubMed ID: 9040728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.
    Misiura MB; Lourens S; Calhoun VD; Long J; Bockholt J; Johnson H; Zhang Y; Paulsen JS; Turner JA; Liu J; Kara B; Fall E;
    J Int Neuropsychol Soc; 2017 Feb; 23(2):159-170. PubMed ID: 28205498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.
    Paulsen JS; Zimbelman JL; Hinton SC; Langbehn DR; Leveroni CL; Benjamin ML; Reynolds NC; Rao SM
    AJNR Am J Neuroradiol; 2004; 25(10):1715-21. PubMed ID: 15569736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
    Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease.
    Jurgens CK; van de Wiel L; van Es AC; Grimbergen YM; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
    J Neurol; 2008 Nov; 255(11):1785-91. PubMed ID: 19156490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.
    Harrington DL; Long JD; Durgerian S; Mourany L; Koenig K; Bonner-Jackson A; Paulsen JS; ; Rao SM
    Mov Disord; 2016 Nov; 31(11):1664-1675. PubMed ID: 27620011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in functional connectivity of cortico-basal ganglia networks in manifests and premanifest huntington's disease.
    Gargouri F; Messé A; Perlbarg V; Valabregue R; McColgan P; Yahia-Cherif L; Fernandez-Vidal S; Ben Hamida A; Benali H; Tabrizi S; Durr A; Lehéricy S
    Hum Brain Mapp; 2016 Nov; 37(11):4112-4128. PubMed ID: 27400836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat.
    Ruocco HH; Lopes-Cendes I; Li LM; Santos-Silva M; Cendes F
    Braz J Med Biol Res; 2006 Aug; 39(8):1129-36. PubMed ID: 16906288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional subcortical shape analysis in premanifest Huntington's disease.
    Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
    Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography.
    Sax DS; Powsner R; Kim A; Tilak S; Bhatia R; Cupples LA; Myers RH
    Mov Disord; 1996 Nov; 11(6):671-7. PubMed ID: 8914093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.